Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: A pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE v Everolimus Eluting Coronary Stent System in the Treatment of Patients with de Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE v Everolimus Eluting Coronary Stent System [EECSS]

JACC: Cardiovascular Interventions

Volumn 3, Issue 12, 2010, Pages 1220-1228

  Caixeta, Adriano ^a   Lansky, Alexandra J ^a   Serruys, Patrick W ^b   Hermiller, James B ^c   Ruygrok, Peter ^d   Onuma, Yoshinobu ^b   Gordon, Paul ^e   Yaqub, Manejeh ^f   Miquel Hebert, Karine ^f   Veldhof, Susan ^f   Sood, Poornima ^f   Su, Xiaolu ^f   Jonnavithula, Lalitha ^f   Sudhir, Krishnankutty ^f   Stone, Gregg W ^a  

^a NewYork Presbyterian Hospital   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c St Vincent Heart Center of Indiana   (United States)

^d Cardiovascular Service   (New Zealand)

^e MIRIAM HOSPITAL   (United States)

^f ABBOTT VASCULAR   (United States)

Author keywords

drug eluting stent(s); percutaneous coronary intervention; randomized clinical trial

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; EVEROLIMUS; PACLITAXEL;

ARTICLE; CORONARY ARTERY DISEASE; CORONARY ARTERY THROMBOSIS; DRUG ELUTING STENT; DRUG SAFETY; HEART INFARCTION; HUMAN; META ANALYSIS; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVASCULARIZATION; RISK REDUCTION; STENT THROMBOSIS; SYSTEMATIC REVIEW; TARGET LESION REVASCULARIZATION; TARGET VESSEL REVASCULARIZATION;

ANGIOPLASTY, BALLOON, CORONARY; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ASPIRIN; CONFIDENCE INTERVALS; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; PACLITAXEL; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; RISK REDUCTION BEHAVIOR; SIROLIMUS; TICLOPIDINE; TIME FACTORS;

EID: 78651427578     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2010.07.017     Document Type: Article

References (27)

1. J.W. Moses, M.B. Leon, J.J. Popma SIRIUS Investigators Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery N Engl J Med 349 2003 1315 1323
2. G.W. Stone, S.G. Ellis, and D.A. Cox A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease N Engl J Med 350 2004 221 231
3. A. Kastrati, A. Dibra, and C. Spaulding Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction Eur Heart J 28 2007 2706 2713 (Pubitemid 350139205)
4. J. Daemen, P. Wenaweser, and K. Tsuchida Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study Lancet 369 2007 667 678
5. G.W. Stone, J.W. Moses, and S.G. Ellis Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents N Engl J Med 356 2007 998 1008
6. A. Kastrati, J. Mehilli, and J. Pache Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents N Engl J Med 356 2007 1030 1039
7. A.V. Finn, M. Joner, and G. Nakazawa Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization Circulation 115 2007 2435 2441
8. M. Pfisterer, H.P. Brunner-La Rocca, P.T. Buser BASKET-LATE Investigators Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents J Am Coll Cardiol 48 2006 2584 2591
9. G.W. Stone, S.G. Ellis, L. Cannon TAXUS V Investigators Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial JAMA 294 2005 1215 1223
10. J.R. Nebeker, R. Virmani, and C.L. Bennett Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project J Am Coll Cardiol 47 2006 175 181
11. S.H. Hofma, W.J. van der Giessen, and B.M. van Dalen Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation Eur Heart J 27 2006 166 170
12. R. Hoffmann, M.C. Morice, and J.W. Moses Impact of late incomplete stent apposition after sirolimus-eluting stent implantation on 4-year clinical events: intravascular ultrasound analysis from the multicentre, randomised, RAVEL, E-SIRIUS and SIRIUS trials Heart 94 2008 322 328
13. A. Maehara, G.S. Mintz, and A.J. Lansky Volumetric intravascular ultrasound analysis of paclitaxel-eluting and bare metal stents in acute myocardial infarction: the harmonizing outcomes with revascularization and stents in acute myocardial infarction intravascular ultrasound substudy Circulation 120 2009 1875 1882
14. G. Nakazawa, A.V. Finn, and M. Vorpahl Incidence and predictors of drug-eluting stent fracture in human coronary artery: a pathologic analysis J Am Coll Cardiol 54 2009 1924 1931
15. P.W. Serruys, P. Ruygrok, and J. Neuzner A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial EuroIntervention 2 2006 286 294
16. G.W. Stone, M. Midei, W. Newman SPIRIT III Investigators Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial JAMA 299 2008 1903 1913
17. Y. Onuma, P.W. Serruys, N. Kukreja SPIRIT II and III Investigators Randomized comparison of everolimus- and paclitaxel-eluting stents: pooled analysis of the 2-year clinical follow-up from the SPIRIT II and III trials Eur Heart J 31 2010 1071 1078
18. D.E. Cutlip, S. Windecker, R. Mehran Academic Research Consortium Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351
19. G.W. Stone, A. Rizvi, W. Newman SPIRIT IV Investigators Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease N Engl J Med 362 2010 1663 1674
20. E. Kedhi, K.S. Joesoef, and E. McFadden Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial Lancet 375 2010 201 209
21. Lansky AJ, Applegate RJ, Hermiller JB, et al. Side-branch occlusion with Xience V everolimus-eluting and Taxus Express paclitaxel-eluting stents: 2-year results from the SPIRIT III randomized trial. Paper presented at: Transcatheter Cardiovascular Therapeutics Conference; September 23, 2009; San Francisco, CA.
22. A. Dibra, A. Kastrati, J. Mehilli ISAR-DIABETES Study Investigators Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients N Engl J Med 353 2005 663 670
23. M. Billinger, J. Beutler, and K.R. Taghetchian Two-year clinical outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents in diabetic patients Eur Heart J 29 2008 718 725
24. C. Stettler, S. Allemann, and S. Wandel Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis BMJ 337 2008 a1331
25. A. Caixeta, M.B. Leon, and A.J. Lansky 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents J Am Coll Cardiol 54 2009 894 902
26. A.C. Gingras, B. Raught, and N. Sonenberg mTOR signaling to translation Curr Top Microbiol Immunol 279 2004 169 197
27. S.W. Lagakos The challenge of subgroup analyses: reporting without distorting N Engl J Med 354 2006 1667 1669